Naomi Mark, LCSW
Mental Health Provider Type: Social worker
States Served: New York
Languages Spoken: English, Hebrew, Yiddish
Address: 915 West End Avenue,
New York, New York 10025
New York, New York 10025
Phone number: (917) 301-5902
Email: naomismark@gmail.com
Age of Patients Accepted:
- Young adults 18-35
- Adults 36-60
- Adults 60 and older
Experience with Treatments/Conditions:
- Autologous
- Allogeneic
- CAR T-cell therapy
- Graft-versus-Host Disease
Disease Experience:
- Leukemia
- Lymphoma, Hodgkin Disease
- Multiple Myeloma
Additional areas of Expertise:
- Anxiety/Depression
- Trauma/PTSD
- Cognitive behavioral therapy for insomnia (CBT-I)
- Sexual health
- Couples therapy
- Family therapy
- Parenting
Where Service is Provided: Private practice
Fee Structure: Out-of-network private insurance, Sliding scale based on ability to pay
Background: Ms. Marks worked as a Senior Clinical Social Worker at Memorial Sloan Kettering Cancer Center for over seven years. For part of that time, she worked with the Bone Marrow Transplant team following patients from diagnosis through the early survivorship period. She found that the support she was able to provide helped patients cope with the stress and move towards healing.
She has worked primarily with patients undergoing an autologous stem cell transplant (transplant using donor cells) but is familiar with transplants using donor cells (allogeneic transplants) and graft-versus-host disease (GVHD). She has helped patients and their families deal with secondary cancers, relapse, end of life issues and grief and loss. She has not yet had experience working with CAR T-cell therapy patients.
She has worked primarily with patients undergoing an autologous stem cell transplant (transplant using donor cells) but is familiar with transplants using donor cells (allogeneic transplants) and graft-versus-host disease (GVHD). She has helped patients and their families deal with secondary cancers, relapse, end of life issues and grief and loss. She has not yet had experience working with CAR T-cell therapy patients.